Clinical outcomes following a switch from Remicade® to the biosimilar CT-P13 in inflammatory bowel disease patients: a prospective observational cohort study

LJT Smits, LAAP Derikx, DJ de Jong… - Journal of Crohn's …, 2016 - academic.oup.com
Abstract Background and Aims: The biosimilar of Remicade®, CT-P13, recently entered the
European market. Clinical data on switching from Remicade® to CT-P13 in inflammatory …
被引用次数：161 相关文章

Clinical Outcomes Following a Switch from Remicade® to the Biosimilar CT-P13 in Inflammatory Bowel Disease Patients: A Prospective Observational Cohort Study

LJT Smits, LAAP Derikx, DJ de Jong… - Journal of Crohn's …, 2016 - pubmed.ncbi.nlm.nih.gov
Background and aims The biosimilar of Remicade®, CT-P13, recently entered the European
market. Clinical data on switching from Remicade® to CT-P13 in inflammatory bowel …

Clinical Outcomes Following a Switch from Remicade® to the Biosimilar CT-P13 in Inflammatory Bowel Disease Patients: A Prospective Observational Cohort Study.

LJT Smits, LAAP Derikx, DJ de Jong… - Journal of Crohn's …, 2016 - search.ebscohost.com
Abstract Background and Aims: The biosimilar of Remicade®, CT-P13, recently entered the
European market. Clinical data on switching from Remicade® to CT-P13 in inflammatory …

[引用][C] Clinical Outcomes Following a Switch from Remicade (R) to the Biosimilar CT-P13 in Inflammatory Bowel Disease Patients: A Prospective Observational Cohort …

LJT Smits, LA Derikx, DJ de Jong, RS Boshuizen… - 2016 - repository.ubn.ru.nl
BACKGROUND AND AIMS: The biosimilar of Remicade (R), CT-P13, recently entered the
European market. Clinical data on switching from Remicade (R) to CT-P13 in inflammatory …

Clinical outcomes following a switch from Remicade® to the biosimilar CT-P13 in inflammatory bowel disease patients: A prospective observational cohort study

LJT Smits, LAAP Derikx… - … of Crohn's and …, 2016 - researchinformation.amsterdamumc …
Abstract Background and Aims: The biosimilar of Remicade®, CT-P13, recently entered the
European market. Clinical data on switching from Remicade® to CT-P13 in inflammatory …

Clinical Outcomes Following a Switch from Remicade® to the Biosimilar CT-P13 in Inflammatory Bowel Disease Patients: A Prospective Observational Cohort Study.

LJ Smits, LA Derikx, DJ de Jong… - Journal of Crohn's & …, 2016 - europepmc.org
Methods Remicade®-treated IBD patients at the Radboud university medical centre who
switched to CT-P13 were included in this prospective observational cohort study. Primary …